On Friday, Shares of Weatherford International plc (NYSE:WFT), lost -1.18% to $12.51.
On June 17, Weatherford International, introduced the commercial release of the IntegraLine™ liner system with swage technology at the International Association of Drilling Contractors (IADC) World Drilling 2015 Conference and Exhibition. Operators recently are more likely to encounter challenging well environments than routine ones. Designed and engineered by Weatherford for critical environments, the IntegraLine high-performance liner system provides maximum reliability in critical applications such as ultra deepwater, extended-reach, and sour-gas wells with high pressures and temperatures.
The IntegraLine liner system is comprised of three premium components: the polished bore receptacle, liner-top packer, and rotational hanger. The packer features swage sealing technology that forms an anti-extrusion, gas-tight barrier between the outer diameter of the packer body and the inner diameter of the host casing. This configuration reduces equipment failures that may threaten well integrity, allowing clients to achieve total depth efficiently while withstanding harsh conditions. Alternative components are also accessible to create a fit-for-purpose liner-hanger solution for specific, complex applications.
Weatherford International public limited company provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide.
Shares of Curis, Inc. (NASDAQ:CRIS), inclined 5.70% to $3.15, during its last trading session.
On May 31, Curis, Inc. declared results from the accomplished dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907, an oral dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes. Data were presented at the Annual Meeting of American Society of Clinical Oncology (ASCO) that is being held in Chicago, IL. At the recommended Phase 2 dose and plan, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL). Two complete responses (CRs) and 4 partial responses (PRs) were stated in 10 response evaluable patients with DLBCL, counting 3 responses (1 CR and 2 PRs) in patients with transformed follicular lymphoma (t-FL/DLBCL), a very difficult to treat subset of DLBCL. One patient with HL practiced partial response out of a total of 12 response evaluable patients with HL. In addition, stable disease (SD) has been observed in 25 of 44 response evaluable patients across various lymphomas and multiple myeloma (MM).
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma.
Finally, Mattson Technology Inc. (NASDAQ:MTSN), ended its last trade with -1.42% loss, and closed at $3.47.
Mattson Technology, declared that Fusen E. Chen, the company’s president and chief executive officer, and J. Michael Dodson, chief operating and chief financial officer, will take part in the Seventh Annual CEO Investor Summit 2015, Wednesday, July 15, 2015 in San Francisco, California.
Mattson Technology, Inc. designs, manufactures, markets, and supports semiconductor wafer processing equipment for use in fabricating integrated circuits (ICs) worldwide. Its dry strip products comprise the SUPREMA strip system, which is used for production and process development at 20 nanometer technology nodes and beyond by semiconductor companies
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
